Warfarin control in patients transitioning to warfarin after non-vitamin K oral anticoagulant (NOAC) therapy

被引:5
作者
Bernaitis, Nijole [1 ,2 ]
Badrick, Tony [3 ]
Davey, Andrew K. [1 ,2 ]
Crilly, Julia [1 ,4 ]
Anoopkumar-Dukie, Shailendra [1 ,2 ]
机构
[1] Griffith Univ, Qual Use Med Network, Southport, Qld, Australia
[2] Griffith Univ, Sch Pharm & Pharmacol, Gold Coast Campus, Southport, Qld 4222, Australia
[3] RCPA, Qual Assurance Programs, St Leonards, NSW, Australia
[4] Gold Coast Hlth, Dept Emergency Med, Southport, Qld, Australia
关键词
Anticoagulant; International normalized ratio; Warfarin; ATRIAL-FIBRILLATION PATIENTS; MANAGEMENT; DRUG;
D O I
10.1007/s11239-018-1719-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Warfarin has long been the most widely prescribed oral anticoagulant. Introduction of non-vitamin K oral anticoagulants (NOACs) has provided anticoagulant options but also presented the potential challenge of transitioning between agents. Changes from NOACs to warfarin are particularly problematic with delays to therapeutic effect and limited real-world data regarding the impact on warfarin control. The aim of this study was to investigate the frequency of switching anticoagulants and the effect on warfarin control. Retrospective data was collected for patients at a warfarin program in Queensland Australia who had exited the program for NOACs plus those who had reverted to warfarin. Data included documented reasons for change and International Normalised Ratio (INR) results with time in therapeutic range (TTR) calculated as a measure of warfarin control. Over 5 years, a total of 3036 patients ceased warfarin to commence a NOAC but 142 (4.7%) reverted to warfarin. Majority of patients (60.6%) reverted to warfarin within 6 months of trialling NOACs with a median of 6 days to therapeutic INR. There was no significant difference in warfarin control before changing to NOACs and after reverting to warfarin (mean TTR 75%) but significantly more frequent testing and lower doses were required to achieve this control. Transitions from warfarin to NOACs results in almost a week to therapeutic effect and warfarin therapy may be further complicated by a need for increased frequency of testing. Further studies are required to refine transition strategies particularly from warfarin to NOAC and minimise potential risks to patients.
引用
收藏
页码:461 / 465
页数:5
相关论文
共 50 条
  • [31] Arrhythmia Recurrence After Atrial Fibrillation Ablation: Impact of Warfarin vs. Non-Vitamin K Antagonist Oral Anticoagulants
    Wen, Songnan
    Pislaru, Cristina
    Monahan, Kristi H.
    Barnes, Stephanie M.
    Hodge, David O.
    Packer, Douglas L.
    Pislaru, Sorin, V
    Asirvatham, Samuel J.
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (05) : 891 - 901
  • [32] Non-vitamin K oral anticoagulant use after cardiac surgery is rapidly increasing
    Beller, Jared P.
    Krebs, Elizabeth D.
    Hawkins, Robert B.
    Mehaffey, J. Hunter
    Quader, Mohammed A.
    Speir, Alan M.
    Kiser, Andy C.
    Joseph, Mark
    Yarboro, Leora T.
    Teman, Nicholas R.
    Ailawadi, Gorav
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2020, 160 (05) : 1222 - 1230
  • [33] Non-vitamin K oral antagonist (NOAC) compared to vitamin K antagonist (VKA) in left ventricular thrombus
    Al-Kaf, Fahmi
    Al Basiri, Saleh
    Al Ash'hab, Yasser
    Otain, Mohammad
    Al Askary, Hafed
    Al Khushail, Abdullah
    Robert, Asirvatham Alwin
    Al Fagih, Ahmed
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2024, 13 (06) : 2485 - 2490
  • [34] Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients
    Iftimi, Adina A.
    Rodriguez-Bernal, Clara L.
    Peiro, Salvador
    Bonanad, Santiago
    Ferrero-Gregori, Andreu
    Hurtado, Isabel
    Garcia-Sempere, Anibal
    Sanfelix-Gimeno, Gabriel
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) : 200 - 208
  • [35] Warfarin vs non-vitamin K oral anticoagulants for left atrial appendage thrombus: A meta-analysis
    Murtaza, Ghulam
    Turagam, Mohit K.
    Atti, Varunsiri
    Garg, Jalaj
    Boda, Urooge
    Velagapudi, Poonam
    Akella, Krishna
    Natale, Andrea
    Gopinathannair, Rakesh
    Lakkireddy, Dhanunjaya
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2020, 31 (07) : 1822 - 1827
  • [36] Gastrointestinal bleeding risk of non-vitamin K oral anticoagulants is similar to warfarin - a Japanese retrospective cohort study
    Shirai, Tsuguru
    Yamamoto, Takatsugu
    Kawasugi, Kazuo
    Kuyama, Yasushi
    Kita, Hiroto
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2016, 54 (11) : 841 - 846
  • [37] Ten years of non-vitamin K antagonists oral anticoagulants for stroke prevention in atrial fibrillation: is warfarin obsolete?
    Hammwoehner, Matthias
    Goette, Andreas
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2020, 22 (0O) : 28 - 41
  • [38] Acute Lower Gastrointestinal Bleeding in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice: Characteristics and Clinical Outcome
    Diamantopoulou, Georgia
    Konstantakis, Christos
    Skroubis, George
    Theocharis, George
    Theopistos, Vasilios
    Triantos, Christos
    Thomopoulos, Konstantinos
    GASTROENTEROLOGY RESEARCH, 2019, 12 (01) : 21 - 26
  • [39] Early Administration of Non-Vitamin K Antagonist Oral Anticoagulants for Acute Ischemic Stroke Patients With Atrial Fibrillation in Comparison With Warfarin Mostly Combined With Heparin
    Nomura, Eiichi
    Ohshita, Tomohiko
    Imamura, Eiji
    Wakabayashi, Shinichi
    Kajikawa, Hiroshi
    Hosomi, Naohisa
    Matsumoto, Masayasu
    CIRCULATION JOURNAL, 2015, 79 (04) : 862 - 866
  • [40] Prospective evaluation of anticoagulant reversal with oral vitamin K1 while continuing warfarin therapy unchanged
    Wentzien, TH
    O'Reilly, RA
    Kearns, PJ
    CHEST, 1998, 114 (06) : 1546 - 1550